A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly says its GLP-1 drug in pill form is as safe and effective as Ozempic and other mega-popular injectable drugs for weight loss and lowering blood sugar. The company announ ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...

Orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, has shown positive Phase 3 results in treating type 2 ...